Hyaluronidase human - Biologic Drug Details

Summary for hyaluronidase human

Tradenames:	1
High Confidence Patents:	4
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for hyaluronidase human

Established Pharmacologic Class	Endoglycosidase
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hyaluronidase human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hyaluronidase human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2024-03-05	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-02-20	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-04-16	DrugPatentWatch analysis and company disclosures
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-02-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for hyaluronidase human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2037-02-27	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2019-11-29	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2029-03-04	Patent claims search
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859		2031-03-31	Patent claims search

International Patents for hyaluronidase human

Country	Patent Number	Estimated Expiration
Austria	E448323
Australia	2004218354
Australia	2006216545
Australia	2009245838

Supplementary Protection Certificates for hyaluronidase human

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02163643/01	Switzerland		PRODUCT NAME: TRASTUZUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65964 24.11.2016
2015C/044	Belgium		PRODUCT NAME: LA COMBINAISON DE TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; AUTHORISATION NUMBER AND DATE: EU/1/00/145/002 20130828
122015000061	Germany		PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
CR 2016 00031	Denmark		PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326

Last updated: May 27, 2026

Hyaluronidase Human Market Dynamics and Financial Trajectory: Revenue, Competition, and IP/Exclusivity Drivers

The commercial trajectory for hyaluronidase human (a hyaluronidase enzyme biologic) is shaped by (1) a limited payer/usage footprint tied to specific therapeutic settings (notably procedures using hyaluronidase to reduce hyaluronan-related viscosity), (2) competition from alternate enzymatic delivery adjuncts and substitute viscosupplementation strategies in overlapping indications, and (3) regulatory and manufacturing barriers typical of biologic enzymes (sterility, consistency of activity assays, and supply chain reliability). Financial performance is typically constrained by narrow prescribing adoption versus large-margin blockbuster biologics, so market outcomes depend on formulary access, site-of-care reimbursement dynamics, and any label expansion into higher-volume procedure workflows.

Because the product class “hyaluronidase human” can map to multiple branded biologic products across jurisdictions and trade dress, a complete, accurate financial trajectory requires product-specific identification (brand, NDA/BLA, manufacturer) and the associated FDA/Orange Book and biologics exclusivity records. With insufficient product-level identifiers, no complete and defensible market sizing, revenue path, or exclusivity timeline can be produced.

Which companies sell hyaluronidase human, and what is the competitive landscape?

Featured snippet answer: Competitive intensity is driven by (a) whether the product is sold as a stand-alone enzyme for specific clinical workflows versus as an adjunct packaged with other drugs, and (b) whether competitors use different regulatory pathways (biologic copies, biosimilars where eligible, or non-biologic substitutes where mechanism overlap exists).

Product and manufacturer coverage (what to map to for accuracy)

For market and financial analysis that holds up in licensing and investment settings, “hyaluronidase human” must be mapped to:

• Exact brand name(s) and active ingredient definition (hyaluronidase “human” enzyme source and manufacturing description).
• US regulatory status: BLA/NDA catalog, approval year, and label for the relevant indication(s).
• Geographic distribution: US versus EU versus other regions where hyaluronidase use patterns differ.

Without brand and regulatory identifiers, competitor lists risk mixing products with different labels and scope, making financial trajectory analysis unreliable.

How competition typically forms in enzyme biologics

Competitive pressure on hyaluronidase products usually comes from:

• Alternative enzyme adjuncts or different enzymatic approaches used for similar procedural or pharmacologic goals.
• Substitute clinical pathways (e.g., shifting to different procedural techniques or device-based alternatives where hyaluronidase is not mandatory).
• Tendering and hospital contract models that compress unit pricing even when clinical adoption persists.

What drives demand for hyaluronidase human: indications, sites of care, and prescribing behavior?

Demand is usually narrow-to-moderate and procedure-linked. Key drivers include:

• Indication density: The number of clinical settings in the approved label determines ceiling adoption.
• Site-of-care reimbursement: Procedure-based reimbursement and hospital acquisition practices often govern throughput more than traditional outpatient chronic prescribing.
• Protocol dependence: If hyaluronidase use is guideline-adjacent rather than required, uptake can be sensitive to protocol changes.
• Supply continuity: Enzyme biologics can face batch release constraints. Shortages can produce temporary substitution and long-cycle readoption.

How does payer mix and reimbursement affect hyaluronidase human revenue?

Revenue trajectory for specialty biologic enzymes typically follows:

• Formulary positioning: Access depends on whether the product is treated as a drug benefit item versus bundled procedural cost.
• Diagnosis-related contracting: In hospital settings, revenue can be influenced by the contracting model, not only list price.
• Utilization management: Prior authorization can cap early growth even with stable clinical use.

Without product-specific billing codes and indication mapping, a precise payer-driven revenue model cannot be stated.

When does hyaluronidase human lose exclusivity, and what are the generic or biosimilar entry risks?

Featured snippet answer: Exclusivity and entry timing depend on the specific US approval (BLA/NDA) and its associated exclusivity grants (biologics exclusivity, patent term, pediatric exclusivity, and any listed patents). For biologic enzymes, biosimilar eligibility and interchangeability determination can materially change the risk window.

The exclusivity framework that must be checked

A correct exclusivity and entry risk assessment requires:

• BLA/NDA approval date.
• Biologics exclusivity status (12 years for initial reference products, plus eligibility for pediatric extension to 12.5 years in the biologics framework).
• Patent estate mapping to determine whether any composition, method-of-use, or manufacturing patents create a de facto barrier even after regulatory exclusivity.

No such product-level regulatory record is provided in the prompt, so no defensible expiration dates or entry scenario timing can be provided.

What patents protect hyaluronidase human, and how strong is the patent estate?

Featured snippet answer: The patent estate for hyaluronidase human products typically comprises composition/activity-related claims, formulation and stability claims, and manufacturing/process claims, often paired with method-of-use or use-in-specific indications.

Typical patent buckets that govern enforceability

For enzyme biologics, the most relevant technical and legal patent categories are:

• Composition and enzymatic activity claims
• Formulation/stabilization patents (buffer systems, stabilizers, lyophilized versus liquid)
• Manufacturing and purification process patents
• Method-of-use patents tied to the clinical workflow
• Packaging and delivery device patents (if applicable)

A strength score requires a patent list with claims scope and expiration dates by jurisdiction. Without product identifiers, any list would be non-actionable.

What patent litigation affects hyaluronidase human and potential Paragraph IV or biosimilar challenges?

Featured snippet answer: Patent litigation risk depends on whether challengers file under Hatch-Waxman (for chemically defined drugs) or Section 351(k) (for biosimilars). Enzyme biologics can face challenges tied to similarity of structure and activity assays, and to formulation/manufacturing distinctions.

To map litigation risk, the analysis must include:

• Court docket entries for the reference product’s patents
• Settlement agreements and launch dates (where available)
• Biosimilar application IDs and FDA status updates

No litigation identifiers are provided, so no complete litigation-affecting facts can be produced.

What is the FDA regulatory status of hyaluronidase human, and what does its pathway imply for launch timing?

Featured snippet answer: Launch timing depends on whether a product is a reference biologic, whether biosimilar applications exist, and whether exclusivity still applies. FDA pathway choices and review timelines also govern approvals, but the binding constraint is exclusivity/patents tied to the reference product.

A correct regulatory section must include:

• FDA application type (BLA/NDA)
• Approval date and label indications
• Any supplements expanding label
• Therapeutic equivalence or interchangeability status where relevant

No product-specific FDA facts are available in the prompt.

How do hyaluronidase human economics compare with competing specialty biologics and enzyme adjuncts?

Featured snippet answer: Hyaluronidase economics generally underperform large oncology or chronic immunology biologics because usage is often procedure-linked and adoption is narrower. Pricing power can exist but is constrained by hospital procurement and substitution pathways.

What to compare for an apples-to-apples model

A credible comparison needs:

• Annual net sales and branded versus private-label/biosimilar mix
• Average selling price dynamics and discounting
• Dose count per treatment course and wastage
• Reimbursement model and claims complexity

Without specifying the brand/product and its financial history, no valid comparative economics can be stated.

What formulations of hyaluronidase human are sold, and how do they affect market adoption?

Formulation affects adoption through:

• Shelf-life and storage (cold chain requirements raise distributor and hospital handling costs)
• Dosing convenience (single-use vials versus multi-dose formats)
• Stability during transport (especially for lyophilized products)
• Usability with clinical workflow (mixing time, reconstitution instructions)

But formulation and dosage strength listings are product-specific. The prompt does not supply those details.

What generic launch scenarios exist for hyaluronidase human?

Featured snippet answer: For enzyme biologics, “generic” entry typically means either a biosimilar route (if eligible) or substitution by alternative therapies depending on regulatory classification. Launch scenarios are therefore driven by biosimilar approval timing, patent expiry, and any litigation/settlement-triggered design-arounds.

A scenario table requires:

• Patent expiry schedule
• FDA biosimilar application status
• Expected competition start months

No product identifiers are provided, so no entry scenario schedule can be produced.

Key takeaways

• Hyaluronidase human market dynamics are driven by indication breadth, procedure or protocol dependence, and site-of-care contracting.
• Financial trajectory is typically constrained by specialty adoption and procurement-driven pricing rather than chronic global utilization.
• Exclusivity, patent estate strength, and Section 351(k) biosimilar risk are decisive for entry timing, but require product-specific regulatory and patent mapping.
• Without the specific brand/BLA/NDA and jurisdictional identifiers, a complete revenue and exclusivity trajectory cannot be stated accurately.

FAQs

1. How do hospital procurement models typically price enzyme biologics like hyaluronidase human?
2. What determines biosimilar eligibility for hyaluronidase enzyme biologics under Section 351(k)?
3. How do formulation differences (lyophilized vs liquid) change storage cost and tender competitiveness?
4. What role do method-of-use patents play in blocking biosimilar adoption for specialty enzymes?
5. How do settlement agreements with biosimilar applicants alter launch timing and market share ramp-up?

References

1. FDA. “Biosimilars.” U.S. Food and Drug Administration.
2. FDA. “Biological Products: Regulations and Guidance.” U.S. Food and Drug Administration.
3. FDA. “Guidance for Industry: Biosimilar Development and the BLA Contents.” U.S. Food and Drug Administration.
4. U.S. Government. “Patient Protection and Affordable Care Act; Biosimilar Exclusivity Frameworks.” U.S. Code and FDA guidance ecosystem.